Prochlorperazine (dimaleate)

Prochlorperazine dimaleate is an orally active phenothiazine-type dopamine D2 receptor (D2R) antagonist. Prochlorperazine exhibits anti-cancer activity in vitro against various cancer cell lines. Prochlorperazine dimaleate exhibits IC₅₀ values of 6.4 μM, 4.5 μM and 2.3 μM for NOX1, NOX2 and NOX5, respectively. Prochlorperazine dimaleate has antedesmosidic activity against dengue virus (DENV). Prochlorperazine dimaleate can be used for research on nausea, vomiting, migraine, and schizophrenia^[1][2][3]. In Vitro:Prochlorperazine dimaleate exhibits anticancer potential against various human cancer cell lines (including human glioblastoma GBM8401, U87-MG cells, brain cancer BT478 cells, breast cancer MCF-7 cells, colon cancer SW620 cells, leukemia PLB-985 cells, melanoma COLO829, C32 cells, etc.)^[2].
Prochlorperazine dimaleate (0-30 μM, 26-50 h) significantly inhibited the expression of DENV-2 viral protein (NS3) and viral replication, with an EC₅₀ of 137 nM; it also had inhibitory effects on DENV-1 and Japanese encephalitis virus (JEV), indicating broad-spectrum antiflavin activity^[3]. In Vivo:Prochlorperazine dimaleate (1-5 mg/kg, i.p. and p.o., once daily for 10 days) demonstrates potent anti-DENV-2 activity in the mouse model^[3].